Loma Linda, CANCT03394365Now EnrollingIRB Ready

Post-transplant lymphoproliferative disease Clinical Trial in Loma Linda, CA

Access cutting-edge post-transplant lymphoproliferative disease treatment through this clinical trial at a research site in Loma Linda. Study-provided care at no cost to qualified participants.

Sponsored by Pierre Fabre Medicament

Quick Self-Assessment

See if you qualify for this Loma Linda location

Preparing your pre-screening questions...

Expert Care in Loma Linda

Access post-transplant lymphoproliferative disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related post-transplant lymphoproliferative disease treatment provided free

Apply for This Loma Linda Location

Check if you qualify for this post-transplant lymphoproliferative disease clinical trial in Loma Linda, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Loma Linda

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Loma Linda site if eligible
  4. 4Begin participation

About This Post-transplant lymphoproliferative disease Study in Loma Linda

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.

Sponsor: Pierre Fabre Medicament

Who Can Participate

Inclusion Criteria

Prior SOT of kidney, liver, heart, lung, pancreas, small bowel, or any combination of these (C-SOT); or prior allogeneic HCT (C-HCT). 2. A diagnosis of locally assessed, biopsy-proven EBV+ PTLD. 3. Availability of appropriate partially HLA-matched and restricted tabelecleucel has been confirmed by the sponsor. 4. Measurable, 18F-deoxyglucose (FDG)-avid (Deauville score ≥ 3) systemic disease using Lugano Classification response criteria by positron emission tomography (PET)-diagnostic computed tomography (CT), except when contraindicated or mandated by local practice, then magnetic resonance imaging (MRI) may be used. For participants with treated central nervous system (CNS) disease, a head CT and/or brain/spinal MRI as clinically appropriate will be required to follow CNS disease response per Lugano Classification response criteria. 5. Treatment failure of rituximab or interchangeable commercially available biosimilar monotherapy (C-SOT-R or C-HCT) or rituximab

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Loma Linda?

Yes, this clinical trial (NCT03394365) has an active research site in Loma Linda, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Post-transplant lymphoproliferative disease Treatment Options in Loma Linda, CA

If you're searching for post-transplant lymphoproliferative disease treatment options in Loma Linda, CA, this clinical trial (NCT03394365) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Loma Linda research site is actively enrolling participants for this clinical trial. You'll receive care from experienced post-transplant lymphoproliferative disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all post-transplant lymphoproliferative disease clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Loma Linda, CA

See all rheumatoid arthritis clinical trials recruiting in Loma Linda — not just this study.

Browse Rheumatoid Arthritis Trials in Loma Linda →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Loma Linda?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Loma Linda, CA